Serologicals, which provides biological products and technology solutions for life science firms, says its revenues and net income jumped in the second quarter.

The company (Nasdaq: SERO) is also preparing to raise $300 million.
Serologicals reported $44 million in sales, a 20 percent increase from one year ago. Net income hit $5.4 million, up 377 percent for 2003. Earnings were 18 cents a share, up from 5 cents a year ago.

For the first half of this year, net income is $8.1 million on sales of $80.5 million, 37 percent higher than in 2003.

“Our second quarter and first half results were driven by solid performance across all areas of our company,” said David Dodd, president and CEO, in a statement. “We saw revenue growth in all business segments with strong and improving gross margins.”